^
    Back
    Association details:
    Biomarker:MTAP deletion
    Cancer:Solid Tumor
    Drug:TNG462 (PRMT5 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

    Excerpt:
    ...Documented bi-allelic (homozygous) deletion of MTAP in a tumor detected by next- generation sequencing or absence of MTAP protein in a tumor detected by IHC....
    Trial ID:
    NCT05732831
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2023
    Title:

    TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted solid tumors

    Published date:
    03/15/2023
    Excerpt:
    Oral administration of TNG462 drives dose-dependent antitumor activity including durable tumor regressions and complete responses in cell line- and patient-derived xenograft models. With enhanced potency and selectivity for MTAP-deleted cancer cells...TNG462 has the potential for broader and deeper clinical activity in MTAP-deleted solid tumors...
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-NCI-EORTC 2022
    Title:

    TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of peripheral MTAP-deleted solid tumors

    Published date:
    10/12/2022
    Excerpt:
    Oral administration of TNG462 drives dose-dependent antitumor activity including durable tumor regressions and complete responses in multiple cell line- and patient-derived xenograft models. With enhanced potency and selectivity for MTAP-deleted cancer cells...TNG462 has the potential for broader and deeper clinical activity in peripheral MTAP-deleted solid tumors.